Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $69.8 million.

  • Mereo BioPharma Group's Cash & Equivalents fell 39.52% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year decrease of 39.52%. This contributed to the annual value of $69.8 million for FY2024, which is 21.56% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Cash & Equivalents of $69.8 million as of FY2024, which was up 21.56% from $57.4 million recorded in FY2023.
  • Mereo BioPharma Group's Cash & Equivalents' 5-year high stood at $127.1 million during FY2021, with a 5-year trough of $30.1 million in FY2020.
  • Over the past 3 years, Mereo BioPharma Group's median Cash & Equivalents value was $68.2 million (recorded in 2022), while the average stood at $65.1 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Cash & Equivalents soared by 321.77% in 2021, and later tumbled by 46.36% in 2022.
  • Mereo BioPharma Group's Cash & Equivalents (Yearly) stood at $30.1 million in 2020, then soared by 321.77% to $127.1 million in 2021, then crashed by 46.36% to $68.2 million in 2022, then decreased by 15.78% to $57.4 million in 2023, then rose by 21.56% to $69.8 million in 2024.